Editas Medicine Inc reports results for the quarter ended December 31 - Earnings Summary

Editas Medicine

05/03/2025 23:25

Editas Medicine Inc EDIT.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -23 cents.  The mean expectation of fourteen analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -87 cents to 10 cents per share.

Revenue fell 49% to $30.60 million from a year ago; analysts expected $32.23 million.

Editas Medicine Inc's reported EPS for the quarter was a loss of 55 cents​.

The company reported a quarterly loss of $45.4 million.

Editas Medicine Inc shares had risen by 38.6% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 14.4% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 9 "hold" and 2 "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Editas Medicine Inc is $3.50

This summary was machine generated from LSEG data March 5 at 11:25 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.36
-0.55
Missed
Sep. 30 2024
-0.75
-0.75
Met
Jun. 30 2024
-0.70
-0.82
Missed
Mar. 31 2024
-0.66
-0.76
Missed